Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.

Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, Paszat LF.

BMJ. 2010 Feb 8;340:c693. doi: 10.1136/bmj.c693.

2.

Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.

Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Hamilton-Dutoit S, Garne JP, Ewertz M, Sørensen HT, Pedersen L.

Acta Oncol. 2010 Apr;49(3):305-12. doi: 10.3109/02841860903575273.

3.

Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?

Pritchard KI.

Breast Cancer Res. 2010 Dec 20;12 Suppl 4:S18. doi: 10.1186/bcr2747. No abstract available.

4.

Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors.

Haque R, Shi J, Schottinger JE, Ahmed SA, Cheetham TC, Chung J, Avila C, Kleinman K, Habel LA, Fletcher SW, Kwan ML.

J Natl Cancer Inst. 2015 Dec 1;108(3). pii: djv337. doi: 10.1093/jnci/djv337. Print 2016 Mar.

5.

Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study.

Donneyong MM, Bykov K, Bosco-Levy P, Dong YH, Levin R, Gagne JJ.

BMJ. 2016 Sep 30;354:i5014. doi: 10.1136/bmj.i5014.

6.

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.

Binkhorst L, Mathijssen RH, van Herk-Sukel MP, Bannink M, Jager A, Wiemer EA, van Gelder T.

Breast Cancer Res Treat. 2013 Jun;139(3):923-9. doi: 10.1007/s10549-013-2585-z. Epub 2013 Jun 13.

PMID:
23760858
7.

Interaction of serotonin reuptake inhibitors with tamoxifen.

Andersohn F, Willich SN.

BMJ. 2010 Feb 8;340:c783. doi: 10.1136/bmj.c783. No abstract available.

PMID:
20142323
8.

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA.

J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64.

PMID:
14652237
9.

Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.

Lash TL, Pedersen L, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Hamilton-Dutoit S, Garne JP, Ewertz M, Sørensen HT.

Br J Cancer. 2008 Aug 19;99(4):616-21. doi: 10.1038/sj.bjc.6604533. Epub 2008 Jul 29.

10.

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA.

J Natl Cancer Inst. 2005 Jan 5;97(1):30-9.

PMID:
15632378
11.

Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010.

Dusetzina SB, Alexander GC, Freedman RA, Huskamp HA, Keating NL.

Breast Cancer Res Treat. 2013 Jan;137(1):285-96. doi: 10.1007/s10549-012-2330-z. Epub 2012 Nov 13.

12.

Tamoxifen and CYP 2D6 inhibitors: caution.

[No authors listed]

Prescrire Int. 2011 Jul-Aug;20(118):182-4.

PMID:
21751753
13.

Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.

Le Ray I, Dell'Aniello S, Bonnetain F, Azoulay L, Suissa S.

Breast Cancer Res Treat. 2012 Sep;135(2):603-9. doi: 10.1007/s10549-012-2198-y. Epub 2012 Aug 19.

PMID:
22903687
15.

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N.

J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88.

PMID:
9747868
16.

Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence.

Azoulay L, Dell'Aniello S, Huiart L, du Fort GG, Suissa S.

Breast Cancer Res Treat. 2011 Apr;126(3):695-703. doi: 10.1007/s10549-010-1162-y. Epub 2010 Sep 17.

PMID:
20848186
17.

Tamoxifen therapy for breast cancer and endometrial cancer risk.

Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, Perlman JA, Ford L.

J Natl Cancer Inst. 1999 Oct 6;91(19):1654-62.

PMID:
10511593
18.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Breast International Group (BIG) 1-98 Collaborative Group., Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A.

N Engl J Med. 2005 Dec 29;353(26):2747-57. Erratum in: N Engl J Med. 2006 May 18;354(20):2200. Wardly, Andrew [corrected to Wardley, Andrew ].

19.

Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.

Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH.

J Natl Cancer Inst. 2003 Apr 2;95(7):526-32.

PMID:
12671020
20.

SSRIs and tamoxifen. Why condemn fluoxetine?

Jenkinson ML.

BMJ. 2010 Mar 10;340:c1319. doi: 10.1136/bmj.c1319. No abstract available.

PMID:
20219794

Supplemental Content

Support Center